Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer

NCT02537444 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02537444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
October 31, 2018
Enrollment
78 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer